by The global antidiabetics market size was estimated to be around US$ 98.20 billion in 2023 and is projected to reach US$ 227.50 billion by 2033, indicating a CAGR of 8.76% from 2024 to 2033.
Key Points
- North America has held the largest revenue share of around 39% in 2023.
- Asia Pacific is observed to witness the fastest rate of expansion during the forecast period.
- By product, the insulin segment dominated the antidiabetics market with the highest share in 2023.
- By product, the drug class segment is observed to grow at a significant rate during the forecast period.
- By patient population, the geriatric segment held the dominating share of the market in 2023.
- By route of administration, the oral segment led the market in 2023. The segment is observed to sustain the position.
- By route of administration, the insulin pen/syringe segment is observed to witness the fastest rate of expansion throughout the forecast period.
The market research report on the antidiabetics market provides a comprehensive analysis of various key aspects. It includes the definition, classification, and application of antidiabetics products. The report examines the development trends, competitive landscape, and industrial chain structure within the industry. Furthermore, it presents an overview of the industry, analyzes national policies and planning, and offers insights into the latest market dynamics and opportunities at a global level.
Get a Sample: https://www.precedenceresearch.com/sample/3914
Antidiabetics Market Scope
| Report Coverage | Details |
| Growth Rate from 2024 to 2033 | CAGR of 8.76% |
| Global Market Size in 2023 | USD 98.20 Billion |
| Global Market Size by 2033 | USD 227.50 Billion |
| U.S. Market Size in 2023 | USD 30.26 Billion |
| U.S. Market Size by 2033 | USD 70.09 Billion |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | By Product, By Patient Population, and By Route of Administration |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Read More: AI in Computer Vision Market Size to Rake USD 274.80 Bn by 2033
The report presents the volume and value-based market size for the base year 2023 and forecasts the market’s growth between 2023 and 2032. It estimates market numbers based on product form and application, providing size and forecast for each application segment in both global and regional markets.
Focusing on the global antidiabetics market, the report highlights its status, future forecasts, growth opportunities, key market players, and key market regions such as the United States, Europe, and China. The study aims to present the development of the antidiabetics market by considering factors like Year-on-Year (Y-o-Y) growth, in addition to Compound Annual Growth Rate (CAGR). This approach enables a better understanding of market certainty and the identification of lucrative opportunities.
Regarding production, the report investigates the capacity, production, value, ex-factory price, growth rate, and market share of major manufacturers, regions, and product types. On the consumption side, the report focuses on the regional consumption of antidiabetics products across different countries and applications.
Buyers of the report gain access to verified market figures, including global market size in terms of revenue and volume. The report provides reliable estimations and calculations for global revenue and volume by product type from 2024 to 2033. It also includes accurate figures for production capacity and production by region during the same period.
The research includes product parameters, production processes, cost structures, and data classified by region, technology, and application. Furthermore, it conducts SWOT analysis and investment feasibility studies for new projects.
This in-depth research report offers valuable insights into the antidiabetics market. It employs an objective and fair approach to analyze industry trends, supporting customer competition analysis, development planning, and investment decision-making. The project received support and assistance from technicians and marketing personnel across various links in the industry chain.
The competitive landscape section of the report provides detailed information on xx market competitors. It includes company overviews, financials, revenue generation, market potential, research and development investments, new market initiatives, global presence, production sites, production capacities, strengths and weaknesses, product launches, product range, and application dominance. However, the data points provided only focus on the companies’ activities related to the antidiabetics market.
Prominent players in the market are expected to face tough competition from new entrants. Key players are targeting acquisitions of startup companies to maintain their dominance. The report
Reasons to Purchase this Report:
- Comprehensive market segmentation analysis incorporating qualitative and quantitative research, considering the impact of economic and policy factors.
- In-depth regional and country-level analysis, examining the demand and supply dynamics that influence market growth.
- Market size in USD million and volume in million units provided for each segment and sub-segment.
- Detailed competitive landscape, including market share of major players, recent projects, and strategies implemented over the past five years.
- Comprehensive company profiles encompassing product offerings, key financial information, recent developments, SWOT analysis, and employed strategies by major market players.
Antidiabetic Market Companies
- Sanofi-Aventis
- Takeda Pharmaceuticals
- Eli Lilly
- Oramed Pharmaceuticals
- Boehringer Ingelheim
- Merck & Co. Inc.
- Novo Nordisk
- Bristol-Myers Squibb
- Halozyme Therapeutics
- Pfizer
Segments Covered in the Report
By Product
- Insulin
- Rapid Acting
- Long Acting
- Premixed Insulin
- Short Acting
- Drug Class
- Biguanides
- GLP-Agonists
- Thiazolidinediones
- Sulphonylureas
- SGLT-2
- Alpha-Glucosidase Inhibitors
- DPP-4 Inhibitors
- Meglitinides
By Patient Population
- Pediatric
- Adults
- Geriatric
By Route of Administration
- Oral
- Infusion
- Intravenous
- Insulin Pump
- Insulin Pen/Syringe
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antidiabetics Market
5.1. COVID-19 Landscape: Antidiabetics Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antidiabetics Market, By Product
8.1. Antidiabetics Market Revenue and Volume, by Product, 2024-2033
8.1.1 Insulin
8.1.1.1. Market Revenue and Volume Forecast (2021-2033)
8.1.2. Drug Class
8.1.2.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 9. Global Antidiabetics Market, By Patient Population
9.1. Antidiabetics Market Revenue and Volume, by Patient Population, 2024-2033
9.1.1. Pediatric
9.1.1.1. Market Revenue and Volume Forecast (2021-2033)
9.1.2. Adults
9.1.2.1. Market Revenue and Volume Forecast (2021-2033)
9.1.3. Geriatric
9.1.3.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 10. Global Antidiabetics Market, By Route of Administration
10.1. Antidiabetics Market Revenue and Volume, by Route of Administration, 2024-2033
10.1.1. Oral
10.1.1.1. Market Revenue and Volume Forecast (2021-2033)
10.1.2. Infusion
10.1.2.1. Market Revenue and Volume Forecast (2021-2033)
10.1.3. Intravenous
10.1.3.1. Market Revenue and Volume Forecast (2021-2033)
10.1.4. Insulin Pump
10.1.4.1. Market Revenue and Volume Forecast (2021-2033)
10.1.5. Insulin Pen/Syringe
10.1.5.1. Market Revenue and Volume Forecast (2021-2033)
Chapter 11. Global Antidiabetics Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.1.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.1.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.2.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.2.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.3.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.3.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.6.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.6.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.4.7.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.4.7.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.4.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.4.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Volume Forecast, by Product (2021-2033)
11.5.5.2. Market Revenue and Volume Forecast, by Patient Population (2021-2033)
11.5.5.3. Market Revenue and Volume Forecast, by Route of Administration (2021-2033)
Chapter 12. Company Profiles
12.1. Sanofi-Aventis
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Takeda Pharmaceuticals
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Eli Lilly
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Oramed Pharmaceuticals
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Boehringer Ingelheim
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Merck & Co. Inc.
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Novo Nordisk
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Bristol-Myers Squibb
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Halozyme Therapeutics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Pfizer
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
